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Introduction and Objectives: Patients with either renovascular hypertension (RVH) and/or renal insufficiency (RI) due to
renal artery ostial occlusive disease (RAOOD) can successfully undergo an open surgical reconstruction procedure
(OSRP), but since the publication of Blum et al1 percutaneous balloon stent angioplasty (PTRA  stent) leaving a small
part of the stent within the aorta has become very popular. However, balloon dilatation and stenting does not remove the
atherosclerotic plaque, which is often heavily calcified but leads to disruption of the plaque causing myointimal
hyperplasia and recurrent stenosis. Therefore, a comparison of the two treatment modalities concerning complications
and durability in a prospective randomized design was felt to bring more insight to the discussion.
Methods: From 1998 to 2004, we performed OSRP in 330 patients with RVH and/or RI for various locations of
RAOOD. During this time period, 50 patients (female 18, male 32, mean age 64.4 years) with RAOOD of at least 70%
stenosis (DSA and duplex criteria) in one or both renal arteries, who did not require other aorto/mesenteric/iliac
reconstructive procedures agreed and were randomized to either OSRP (n  25 patients, 49 arteries) or PTRA  stent
(n  25 patients, 28 arteries). Two patients crossed over to surgical treatment. Patients were followed on a regular basis
for 4 years and longer. Endpoints were re-occurrence of RAOOD and impairment of either kidney function or RVH.
Results:We approached 77 arteries. There was no early mortality in either group, but directly procedure-related morbidity
was 13% in the interventional group and 4% in the surgical group. Four-year follow-up mortality was 18% in the
interventional group and 25% in the surgical group. Both groups showed significant improvement of RVH (P < .001 in
each group) as well as improvement or stabilization in patients with insufficient renal function. Freedom from recurrent
RAOOD (>70%) was achieved in 90.1% of the surgical group and 79.9% of the interventional group.
Conclusion: Both treatment modalities showed good early results concerning RVH, kidney function, and renal perfusion.
Despite a higher number of bilateral renal artery reconstructions in patients undergoing OSRP, which was probably due
to the preferred technique of transaortic endarterectomy eliminating the plaque originating in the aorta and usually
extending into both renal arteries, mortality was not higher and procedure-related morbidity was even lower compared
to PTRA stent. These findings and also longer durability of OSRP imply that surgical reconstruction remains the gold
standard for patients with RAOOD before PTRA  stent may be considered. (J Vasc Surg 2009;49:667-75.)Renal artery stenosis is the most frequent cause of
secondary hypertension with a rising prevalence (1% in the
general population of hypertensives, 5% in hospital-based
populations, and up to 40% in hypertension clinics popula-
tion)2 due to the increase of atherosclerotic diseases. The
main goals of treatment for renal artery ostial occlusive
disease (RAOOD) are stabilization or improvement of
renal function and hypertension. The treatment options
include best medical treatment, open surgical reconstruc-
tion, and percutaneous transluminal renal angioplasty
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in 1992 recommended PTRA as the primary procedure for
atherosclerotic renal artery stenosis despite inferior primary
patency compared to surgical reconstruction,3 but at that
time stents were not used routinely and surgery remained
the method of choice for ostial renal artery stenosis.4 Re-
cently, the use of a stent in ostial lesions was reported to
have improved the results of interventional therapy of ath-
erosclerotic lesions in this region up to 84.5% primary
occlusion-free survival rates.1,5,6 The number of publica-
tions favoring surgical reconstructive methods has de-
creased significantly despite the continuing superior results
of surgical reconstruction.7 However, according to Rund-
back et al,8 “of all existing revascularization techniques,
renal artery stent placement is perhaps the most widely
applied and poorly tested”. Although studies comparing
PTRA to surgery or to antihypertensive medication in a
randomized fashion are lacking, PTRA and stent is consid-
ered as the treatment of first choice by radiologists and
cardiologists also for ostial renal artery disease.9
The aim of this prospective randomized study was to
compare the results of open surgical reconstruction proce-
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success, primary and secondary patency, improvement or
cure of hypertension, as well as stabilization or improve-
ment of renal function in patients with atherosclerotic ostial
renal artery disease.
MATERIALS AND METHODS
The study was designed as a single center prospective
randomized study and was approved by the local ethics
committee of the University of Düsseldorf. Data was col-
lected in an Excel spreadsheet (Microsoft Inc, Redmond,
Wash) and processed with SPSS for windows 14.0. (SPSS
Inc, Chicago, Ill) Statistical analysis included t test, 2
square test, Mann-Whitney U test, Friedmann test, Fisher
exact test, as well as Kaplan-Meier analysis.
Inclusion criteria were presence of hemodynamically
relevant (70% diameter reduction in angiography) ostial
renal artery stenosis with hypertension and informed con-
sent of the patient. Exclusion criteria were fibromuscular
dysplasia, dissection or stenosis in combination with renal
artery aneurysms, as well as simultaneous reconstructions
for aortic aneurysm or aorto/mesenteric/iliac occlusive
disease. All cases were discussed in our nephrovascular
weekly conference which was started in 1978 by the study
committee consisting of a vascular surgeon, a nephrologist,
and an interventional radiologist. Both surgical reconstruc-
tion and interventional therapy had to be judged possible
on the basis of morphological appearance before random-
ization. The patient was informed about the treatment
options by the vascular surgeon and the radiologist inde-
pendently and gave his consent before randomization to
the two treatment possibilities. Pulling of an unmarked
envelope with the defined treatment by the vascular sur-
geon and the nephrologist completed randomization. The
definite decision on treatment (PTRA alone or with stent,
surgical thromboendarterectomy or aortorenal bypass) was
left to the performing radiologist or vascular surgeon. Data
was analyzed based on the actual treatment received.
Between January 1, 1998, and December 31, 2004, 50
patients could be randomized out of 330 patients who
underwent surgical treatment of their renal arteries during
the same period (surgical reconstruction of 628 renal arter-
ies, 256 patients with bilateral reconstruction, 49 patients
with restenoses). A total of 149 patients required a simul-
Table I. Patient characteristics concerning gender, age, an
PTRA
No. of patients 22
Men/Women 12/10
Age / SD (mean and range) 66 / 9 (44 to 8
Smoking (20 pack years) 2 (9%)
PAOD 13 (59%)
Diabetes mellitus 6 (27%)
Hyperlipidemia 15 (68%)
Coronary artery disease 12 (55%)
PTRA, Percutaneous transluminal renal angioplasty; SD, standard deviationtaneous surgical procedure, 114 patients did not agree torandomization and 17 patients were excluded due to tech-
nical reasons (10 PTRA, 7 surgical reconstructions). Dur-
ing the same time period, 94 patients received interven-
tional treatment of their renal arteries, 85% received PTRA
with stent. Despite planned numbers of 25 patients per
treatment group, 1 patient proved finally to be unsuitable
for PTRA only shortly before interventional treatment, 1
patient suddenly demanded surgical reconstruction despite
given consent to randomization, and 1 patient refused
participation in the study before receiving any treatment.
The definite group samples were, therefore, 22 patients in
the PTRA and stent group and 27 patients in the surgical
group. The mean hospital length of stay was 18 / 9
days for the surgical group and 10 / 9 days for the
interventional group.
The mean age of the surgical group patients was 62-
years-old (range, 49 to 77) compared to 66-years-old
(range, 44 to 84) in the interventional group. The inci-
dence of diabetes and peripheral arterial occlusive disease
(PAOD) differed slightly (27% diabetics in the interven-
tional group, 11% in the operative group, PAOD54% in the
interventional group, 40% in the operative group), whereas
the incidence of coronary artery disease was similar (54% in
the interventional group, 55% in the operative group)
(Table I).
Serum creatinine as well as urea levels were slightly
higher in the interventional group (mean creatinine 1.59
mg/dL, mean urea 68.5 mg/dL in the interventional
group, mean creatinine 1.33 mg/dL, mean urea 44.5
mg/dL in the operative group [P  .218 for creatinine]
whereas the systolic and diastolic blood pressure were sim-
ilar (mean systolic blood pressure 170 / 22 mm Hg in
the surgical group, 169 / 18 mm Hg in the interven-
tional group [P .619], mean diastolic blood pressure
88/ 10 mmHg in the surgical group, and 87 / 11
mm Hg in the interventional group [P  .514]. Blood
pressure was measured three times with the patient sitting
after a period of 10 minutes at rest. Mean of the obtained
values were used for further analysis. Four patients received
1 antihypertensive drug (1 interventional group, 3 surgical
groups), 11 patients/two drugs (6 surgical groups, 5 inter-
ventional groups), 16 patients/3 drugs (10 surgical
groups, 6 interventional groups), 11 patients/4 drugs (5
surgical groups, 6 interventional groups) and 7 patients/5
k factors
Surgery Statistical analysis
27
19/8 P  .253 (2)
62 / 8.3 (49 to 77) P  .178 (t test)
16 (60%) P  .01 (2)
11 (41%) P  .201 (2)
3 (11%) P  .074 (2)
23 (85%) P  .233 (2)
14 (52%) P  .944 (2)
D, peripheral arterial occlusive disease.d ris
4)drugs (3 surgical groups, 4 interventional group). There
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patients included, but the nephrologist co-author inter-
vened if the medication was not sufficiently used before
agreeing to surgery.
In the PTRA group, 6 patients underwent bilateral
treatment, while 16 patients were treated for unilateral
involvement. The technique of the interventional proce-
dure consisted of angioplasty, which was followed by stent
placement into 22 renal arteries (Palmaz-Stent, Johnson &
Johnson, Langhorne, Pa, Wallstent, Boston Scientific,
Natick, Mass, Jostent, Abbott, Abbott Park, Ill/Herku-
link-Stent, Boston Scientific, Natick, Mass), six renal arter-
ies were treated by PTRA only because the result did not
warrant stent placement. There were three single kidneys
treated in this group. In the operative group, 22 underwent
bilateral reconstruction, five on one side only due to uni-
lateral disease out of which 1 patient had a single kidney.
Surgery was performed under general anesthesia through a
midline incision. Transaortic renal thromboendarterec-
tomy with subsequent direct suture of the aorta was per-
formed for reconstruction of 45 renal arteries, four renal
arteries were reconstructed by aortorenal bypass graft using
the greater saphenous vein for replacement. Intraopera-
tively, one kidney was perfused with cold (4°C) Ringer
Lactate containing 2.500 IU heparin and 40 ug alprostadil.
Technical details have been described in previous publica-
tions.10 The higher incidence of bilateral treatment in the
operative group is mainly explained by the more aggressive
intra-
operative approach to desobliterate both renal arter-
ies through a transaortic approach (contralateral stenosis
60% in 13 cases, 50 to 60% in 4 cases, and 40 to 50% in 3
cases). In addition, PTRA was planned bilaterally in 5 more
patients in the interventional group but was not performed
due to occlusion of the contralateral renal artery or segmen-
tal arteries in three cases identified during angiography for
treatment of the second renal artery, due to technical
reasons in 1 patient and due to operative conversion after
sudden thrombosis of the primarily interventionally treated
artery in one case.
Renal function was compared by mean creatinine and
urea levels before the operation and at time points T0-3
(preoperatively, 1 month, 1 year, 4 years). Hypertension
was compared by subsequent measurements at these inter-
vals per patient. According to Rundback et al,8 improve-
ment of hypertension was estimated if systolic blood pres-
sure was 140 mm Hg and diastolic blood pressure was
90 mm Hg on the same or reduced number of medica-
tions was achieved after treatment. Cure was anticipated if
blood pressure was normal without any antihypertensive
medication. Failure was considered if blood pressure re-
mained uncontrollable under any medication or increase in
antihypertensive medication was noted at the end of the
study.
Complications were divided into directly procedure-
related (occlusion of renal artery, embolization, bleeding
needing transfusion, or re-intervention, dissection of renal
artery), and overall perioperative complications.Patency was verified by duplex ultrasound scan exami-
nation during the hospital stay as well as after 1 month, 1
year, and 4 years. Follow-up was performed by color duplex
ultrasound scan. Re-stenosis was suspected if peak systolic
velocity increased 2 m per second and/or resistive indices
differed 0.05 between both sides.7 In case of deteriorated
renal function or impairment of hypertension in between
the examination dates, the patients were readmitted to our
hospital for further examination. In case of presumed re-
stenosis due to duplex ultrasound scan or impairment of
renal function or hypertension, an angiography was per-
formed for confirmation and evaluation of further treat-
ment. Re-stenosis was assumed in cases with 70% stenosis
confirmed by angiography. Choice of treatment for re-
stenosis (interventional, operative, or medication) was
based on the morphological appearance of the stenosis and
discussed between radiologist, nephrologist, and the vascu-
lar surgeon.
RESULTS
The primary technical success rate was 96% in the
surgical group (1 patient underwent PTRA and stent due to
local dissection after transaortic endarterectomy, 1 patient
developed postoperative occlusion of one renal artery) and
90% in the interventional group (P .87 Fisher exact test)
(1 patient underwent surgical correction due to dislocation
of the stent migrating into the iliac artery, 1 patient under-
went immediate surgery due to dislocation of the stent with
occlusion of the renal artery). In addition, one segmental
artery became occluded after interventional treatment
without further operative or interventional revision. The
directly procedure-related morbidity was, therefore, 13%
(3/22) in the interventional group and 7% (2/27) in the
operative group (P  .4 Fisher exact test).
There was one postinterventional hematoma in the
PTRA group as an additional complication without any
further treatment. In the operative group, 1 patient devel-
oped postoperative pneumonia, in another case a localized
hematoma after resection of the greater saphenous vein
occurred but dissolved spontaneously. There was one case
of postoperative ileus without further surgery. The overall
complication rate was, therefore, 18% for the interventional
group and 19% in the operative group which was compara-
ble (P  .65 Fisher exact test).
No patient died within 30 days of the operative or
interventional procedure. During the follow-up, 11 pa-
tients died, the majority due to complications of cardiovas-
cular disease in the further course of the study. The overall
mortality rate was 18% in the interventional group (4/22)
and 26% in the operative group (7/27) (P .8 Fisher exact
test). The mean duration of follow-up was 54 months, no
patient was lost to follow-up.
Concerning the development of serum creatinine lev-
els, there was stabilization in the operative group and a
significant (P  .044, t test for matched pairs) trend to
improvement in the PTRA group, whose baseline values
before treatment were slightly worse compared to the ones
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observed regarding the level of urea.
A significant improvement of hypertension could be
achieved in both groups in regard to the systolic as well as to
the diastolic blood pressure (P  .01 for both groups
systolic blood pressure, P  .03 for interventional group
diastolic, P  .01 for operative group diastolic blood pres-
sure, t test for matched pairs) (Figs 2 and 3).
The difference in systolic and diastolic blood pressure
was not significant between the two groups (P  .733
systolic blood pressure, P .489 diastolic blood pressure).
Improvement of hypertension was achieved in 20 sur-
gical and 14 interventional patients, cure was observed in 2
Fig 1. Mean serum creatinine levels (/ 2  stand
postoperatively (T1 1 month, T2 1 year, T3 4 years).
Fig 2. Mean systolic blood pressure (/ 2  stan
postoperatively (T1 1 month, T2 1 year, T3 4 years).surgical and 2 interventional patients, failure to respondwas noted in 5 operative and 6 interventional patients (P
.72 2 test).
Concerning antihypertensive medication, 4 patients (2
surgical group, 2 interventional group) did not need fur-
ther antihypertensive treatment, 5 patients/1 antihyper-
tensive drug (1 interventional group, 4 surgical group), 10
patients/2 antihypertensive drugs (6 surgical group, 4 in-
terventional group), 17 patients/3 antihypertensive drugs
(7 surgical group, 10 interventional group), 12 patients/4
antihypertensive drugs (8 surgical group, 4 interventional
group) and 1 patient in the interventional group required 5
antihypertensive drugs.
There were 11 re-stenoses in the course of the study (8
rror of the mean [SEM]) in the two groups pre- and
error of the mean [SEM]) in both groups pre- andard edardin the interventional group, 3 in the operative group). Of
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was interventional in 4 cases and surgical in 5 cases. In the
operative group, treatment of a stenosed aortorenal bypass
13 months after surgery was interventional (PTRA and
stent), a postoperative occlusion of a right renal artery after
bilateral thromboendarterectomy was not revised due to
the general status of the patient, an occlusion of a left renal
artery after unilateral thromboendarterectomy 38 months
after surgery was not attempted due to the general status of
the patient. One re-stenosis after bilateral thromboendar-
terectomy was revised successfully by aortorenal bypass
after 32 months.
Four interventional patients with re-stenosis in the
course of the study were revised operatively due to several
reasons, treatment was interventional in 3 (Table II). Op-
erative treatment was especially advocated, if there was not
only intimal hyperplasia in the stent but also in the adjacent
anatomical regions. Of the 6 patients receiving PTRA
alone, 4 developed re-stenosis which was treated interven-
tionally in 2, surgically in 1, and observed in 1 patient.
The overall primary patency after 4 years was 68% for
Fig 3. Mean diastolic blood pressure (/ 2 standar
postoperatively (T1 1 month, T2 1 year, T3 4 years).
Table II. Technical results and repeat procedures perform
T0
Renal arteries patent after PTRA 29
PTRA 2 Failure
Re-stenosis and management 2 Stent-dislocation and
operative revision
Renal arteries patent after surgery 49
Surgery 2 Failure
Re-stenosis and management 1 Occlusion, observation
1 Dissection and PTRA
PTRA, Percutaneous transluminal renal angioplasty.renal arteries treated in the interventional group and 88% ofpatients treated in the surgical group (P  .097 log-rank)
(Fig 4).
After treatment for re-stenoses, the secondary patency
after 4 years was 90% for the surgical group and 80% for the
interventional group (P  .20 log-rank) (Fig 5). Patients
treated for restenosis by a different procedure than origi-
nally randomized were counted as unsuccessful in relation
to the primary chosen treatment.
DISCUSSION
Themain goals for treatment of renal artery stenosis are
the control of hypertension as well as the improvement or
maintenance of renal function. Both treatment options
were equally effective in achieving these goals. The primary
technical success rates were slightly superior in the surgical
group (96% to 90%, P  .87 Fisher exact test). Surgical
results after revascularization for renal artery stenosis show
patency rates of about 93%.11 Several reports have shown
especially that the introduction of stent angioplasty im-
proved the technical success rates in interventional treat-
ment for renal artery stenosis from 83%3,12 to 98% or even
r of the mean [SEM]) in both groups measured pre- and
PTRA and surgical reconstruction groups
1 T2 T3 End of study
7 27 23 19
4 Re-stenoses 4 Re-stenoses
2 Re-PTRA 1 Re-PTRA
2 Operative
revision
2 Operative revision
1 Observation
7 47 46 44
1 Re-stenosis 2 Re-stenoses
1 PTRA 1 Operative revision
1 Observationd erroed in
T
2
4100%.1,13,14 The results of PTRA with stent in this study
lumin
slum
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cation of the stent in 2 patients which had to be corrected
surgically. Additionally, six renal arteries were treated by
PTRA alone to the discretion of the treating radiologist, of
which four developed re-stenosis.
The higher incidence of bilaterally treated renal arteries
in the surgical group can be explained by themorphological
appearance of ostial renal artery stenoses which usually
originate in the aorta and therefore often make desoblitera-
tion limited to only one side difficult or even impossible
especially if the contralateral side shows stenosis of more
than 30%. The main principle was not to leave a future
possibly stenosing artery untreated. Nevertheless, the de-
Fig 4. Primary patency rates for percutaneous trans
Fig 5. Secondary patency rates for percutaneous trangree of stenosis of the bilaterally treated arteries was morethan 50% in 17 of 22 cases. Also, there was intention to
treat five more renal artery stenoses bilaterally in the inter-
ventional group, but was felt to be impossible due to
technical reasons in most patients. Accidentally, the num-
ber of single kidneys was greater in the interventional group
(3 to 1). Sivamurthy et al13 reported an incidence of
treatable bilateral stenoses of 45%, in surgical cohorts there
seems to be an increased number of bilateral treatments of
up to 64%.15
Complications are usually divided in two groups: di-
rectly procedure-related and overall. Directly procedure-
related morbidity differed between the two groups (13%
interventional and 7% surgical). The overall complication
al renal angioplasty (PTRA) with stent and surgery.
inal renal angioplasty (PTRA) with stent and surgery.rate was 19% for the surgical group, which is low in com-
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ventional group. Weibull et al3 experienced 17% major
complications (serious clinical complications) in the in-
terventional group and 31% in the surgical group. In addi-
tion, 48% minor complications were noted in the interven-
tional group. Hansen et al15 report a rate of 30% in
perioperative morbidity.
Mortality. The overall mortality rate at the end of the
study period was 18% in the interventional group and 26%
in the operative group. Death occurred mainly due to
complication of ischemic myocardial disease. There was no
perioperative mortality in either group. In the literature,
perioperative mortality in operative cohorts range from
2.6% to 8%,16-18 the rate of complications in interventional
studies is reported to be 4.3 deaths per 1000 patients.9 The
low rate of surgical perioperative mortality in our studymay
also be explained by the exclusion of simultaneous aortic
procedures.
Creatinine. At preoperative workup, the mean level of
creatinine was higher in the PTRA-group than in the
surgical group. This can be partly explained by the greater
number of single kidneys in this group. During the course
of the study, there was a significant trend to improvement
whereas the surgical cohort maintained at preoperative
levels. Themean levels were similar in both groups showing
no statistically significant difference. The difference in re-
sults is, therefore, attributed to the increased baseline level
of creatinine in the PTRA group, however the contrast
media and PTRA did not seem to cause further disturbance
of renal function, it rather appeared that the postinterven-
tional result was more favorable in the PTRA group. Im-
provement and stabilization were also achieved in other
studies,1,3,13,19 Weibull et al3 instead showed higher creat-
inine preoperatively in the operative group with slightly
inferior results in glomerular filtration rate for surgically
treated patients.
Hypertension. In both groups the mean systolic and
diastolic blood pressure values normalized significantly af-
ter restoring renal blood flow. Overall improvement of
hypertension was achieved in 34 of 49 patients (69%, 14
PTRA (64%), 20 operative (74%), cure was achieved in 4 of
49 patients (8%, 2 PTRA (9%), 2 operative (7%), failure was
noted in 11 patients (22%, 6 PTRA (27%), 5 operative
(19%). The stratification of improvement and stabilization
was used from the recommendation stated by Rundback in
2002.8
Patency and management of re-stenosis. Primary
and secondary patency was similar in the surgical group. In
the PTRA and stent group the primary patency of 68% was
improved to 80% patency due to the success of re-PTRA in
3 patients. Primary patency of the surgical group was 88%,
it improved to 90% patency due to re-operation in one case.
Although repeated PTRA is regarded feasible in many
patients developing intimal hyperplasia after PTRA, there
were 6 conversions for surgery during the time of the study
ranging from immediate surgery after an interventional
failure to operative revision 44 months after bilateral
PTRA, because re-stenosis with recurrent hypertension haddeveloped. Weibull et al3 achieved a secondary patency of
90% for PTRA and 97% for surgery after 24 months. The
management of re-stenosis was interventional in 5 patients
and surgical in 5 patients of the interventional treated
patients, it was only interventional in two cases of the
operative group.
Blum et al1 reported secondary patency rates of 92%
during follow-up 60 months after repeat angioplasty and
stenting and advocate this procedure for recurrent stenosis
after stent angioplasty. In our opinion, in the case of
re-stenosis after surgical reconstruction, PTRA may often
become the preferred treatment, because it may be very
useful in managing remaining flaps at the distal end after
thromboendarterectomy or to dilate a stenosed aortorenal
bypass. The cause of re-stenosis after stent angioplasty is
different since it most often occurs at the site of the stent
and has to be considered as the natural response to the local
injury. According to the literature, the use of gold-coated
stents has not solved the problem20 and the use of sirolimus-
coated stents showed no significant improvement in the
rate of re-stenosis (improvement of 14% to 7%).21 There-
fore, we most often prefer the operative intervention in
cases of re-stenosis occurring after primarily successful
PTRA.
The authors acknowledge that this study has limita-
tions. The number of patients should be higher in future
studies to detect differences in treatment we were not able
to detect. Additionally, measurement of estimated glo-
merular filtration rate (eGFR) could have provided more
information on kidney function. Future trials should be
conducted on the basis of intention to treat making
possible errors in interpretation unlikely. Nevertheless,
our trial was able to show a difference in treatment
groups which we would also expect in a larger study with
more defined endpoints.
CONCLUSION
Both interventional as well as surgical treatment of
patients for renal artery stenosis proved to be equally effec-
tive in regard to improvement and/or stabilization of renal
function and in regard to improvement or cure of hyper-
tension. A stent should be used to improve patency. The
primary and secondary patency rates of surgical reconstruc-
tion remain superior compared to interventional therapy
although the use of stents improved the results of the
endovascular procedure significantly in the past.22 In this
study, a benefit concerning lower complication rates in
favor of the interventional treatment was not experienced.
In the management of re-stenosis, surgery was very effec-
tive and may be preferred in patients with residual/recur-
rent stenosis after PTRA, post-surgical re-stenosis can be
treated successfully by PTRA because of the more distal
occurrence of the lesion.
Despite the excellent results of surgical reconstruction,
we are well aware of the increasing numbers of interven-
tionally treated patients. Nevertheless, surgery is still the
gold standard and should be kept in mind especially for
JOURNAL OF VASCULAR SURGERY
March 2009674 Balzer et alyoung patients as well as for re-stenosis after PTRA and for
patients with multiple renal arteries involved.
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Dr Munier Nazzal (Toledo, Ohio). This is a very good study in
an era where you cannot do randomization between stenting and
surgery. But do you think the fact that you hadmore bilateral in the
surgical group have added to the benefit of the procedure?
And another thing, 6 patients were not stented. How many of
those had recurrence? Did this affect your results of endovascular
therapy?
Dr Balzer. There were 4 patients who had balloon angio-
plasty that had restenosis and 3 had to be retreated. In the
bilateral treatment there were 5 more patients intended to be
treated bilaterally in the interventional group. Three of those
developed restenosis and were then treated surgically on both
sides, and 2 were not treated due to increasing of the stenosis on
the contralateral side with shrinking of the kidney, so they were
not treated.
On the other side, there were three single kidneys in the
interventional group. So, of course, the number may give you the
hint of a better benefit; but I think even if the numbers were equal,Dr Vikram Kashyap (Cleveland, Ohio). We recently pub-
lished a series of 125 patients undergoing stenting for renal salvage
and ischemic nephropathy all with elevated creatinines. We found
that estimated glomerular filtration rate (GFR) was very helpful.
Patients that had rapid declines in GFR had improved outcomes
post stenting. Do you have that data, or can you tell us how you
measured renal function long term?
Dr Balzer. Unfortunately, we did not measure GFR, which we
would in any further trials, definitely. But back in 1998 we were not
really thinking about that, unfortunately. And, as you can see, the
creatinine levels were in mean and in total not that high, fortunately.
Dr Gustavo Oderich (Rochester, Minn). I wonder how you
defined restenosis after renal artery stenting. We have noticed in
multiple territories - carotid artery, superior mesenteric artery,
renal arteries - that duplex ultrasound scan criteria used for native
arterial stenosis remarkably changes when a stent is placed. We
have recently found that for mesenteric stents, for example, duplex
ultrasound scan may indicate elevated velocities which do not
correlate with CT or conventional angiography. Can you comment
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imaging method?
Dr Balzer. Duplex ultrasound was only used to monitor the
patients. In cases that we suspected restenosis, we did angiography,
which, of course, gives you a much better picture of definite resteno-
sis. And in cases of any questions, we did measure the pressure
gradient, and there was no patient that didn’t show a stenosis once we
suspected and did an ultrasound scan, unfortunately.
Dr Marc Mitchell (Jackson, Miss). In the surgical arm of your
study, the vast majority of patients had an endarterectomy. Therewere just a few bypasses. How did you decide when to do a renal
artery bypass?
In patients with an in-stent restenosis, did you immediately go
to operative therapy or did you try repeated endovascular proce-
dures first?
Dr Balzer. Well, for those patients that did receive surgical
treatment, there was no time to do interventional treatment.
And the decision to do either aortorenal bypass or thrombo-
endarterectomy was made in the operating room if thromboendar-
terectomy was not feasible due to any reason.
